Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 180 entries
Sorted by: Best Match Show Resources per page
Silicon microring modulator-based RF mixer for millimeter-wave phase-coded signal generation.

Optics letters

Xie Y, Zhuang L, Lowery AJ.
PMID: 28708158
Opt Lett. 2017 Jul 15;42(14):2742-2745. doi: 10.1364/OL.42.002742.

Phase-coded radio frequency (RF) pulses are widely adopted for radar systems as an effective signal format to enable high-range resolution. However, generating such signals conventionally requires high-speed electronics and complex RF circuitry that impose burdens on the system cost...

Cite
Xie Y, Zhuang L, Lowery AJ. Silicon microring modulator-based RF mixer for millimeter-wave phase-coded signal generation. Opt Lett. 2017;42(14):2742-2745doi: 10.1364/OL.42.002742.
Xie, Y., Zhuang, L., & Lowery, A. J. (2017). Silicon microring modulator-based RF mixer for millimeter-wave phase-coded signal generation. Optics letters, 42(14), 2742-2745. https://doi.org/10.1364/OL.42.002742
Xie, Yiwei, et al. "Silicon microring modulator-based RF mixer for millimeter-wave phase-coded signal generation." Optics letters vol. 42,14 (2017): 2742-2745. doi: https://doi.org/10.1364/OL.42.002742
Xie Y, Zhuang L, Lowery AJ. Silicon microring modulator-based RF mixer for millimeter-wave phase-coded signal generation. Opt Lett. 2017 Jul 15;42(14):2742-2745. doi: 10.1364/OL.42.002742. PMID: 28708158.
Copy Download .nbib Format: NLM
Folded orthogonal frequency division multiplexing.

Optics express

Corcoran B, Zhu C, Song B, Lowery AJ.
PMID: 28059351
Opt Express. 2016 Dec 26;24(26):29670-29681. doi: 10.1364/OE.24.029670.

We propose and demonstrate a new sub-carrier multiplexing scheme, utilizing orthogonal, periodic-sinc-shaped sub-carrier spectra. This 'folded' OFDM allows for multi-carrier bands to be generated with the precise, rectangular frequency definition of Nyquist WDM. We show that this scheme can...

Cite
Corcoran B, Zhu C, Song B, et al. Folded orthogonal frequency division multiplexing. Opt Express. 2016;24(26):29670-29681doi: 10.1364/OE.24.029670.
Corcoran, B., Zhu, C., Song, B., & Lowery, A. J. (2016). Folded orthogonal frequency division multiplexing. Optics express, 24(26), 29670-29681. https://doi.org/10.1364/OE.24.029670
Corcoran, Bill, et al. "Folded orthogonal frequency division multiplexing." Optics express vol. 24,26 (2016): 29670-29681. doi: https://doi.org/10.1364/OE.24.029670
Corcoran B, Zhu C, Song B, Lowery AJ. Folded orthogonal frequency division multiplexing. Opt Express. 2016 Dec 26;24(26):29670-29681. doi: 10.1364/OE.24.029670. PMID: 28059351.
Copy Download .nbib Format: NLM
Thank you and goodbye!.

Eye (London, England)

Lotery A.
PMID: 29238074
Eye (Lond). 2017 Dec;31(12):1634. doi: 10.1038/eye.2017.197.

No abstract available.

Cite
Lotery A. Thank you and goodbye!. Eye (Lond). 2017;31(12):1634doi: 10.1038/eye.2017.197.
Lotery, A. (2017). Thank you and goodbye!. Eye (London, England), 31(12), 1634. https://doi.org/10.1038/eye.2017.197
Lotery, A. "Thank you and goodbye!." Eye (London, England) vol. 31,12 (2017): 1634. doi: https://doi.org/10.1038/eye.2017.197
Lotery A. Thank you and goodbye!. Eye (Lond). 2017 Dec;31(12):1634. doi: 10.1038/eye.2017.197. PMID: 29238074; PMCID: PMC5733297.
Copy Download .nbib Format: NLM
In vivo comparison of the charge densities required to evoke motor responses using novel annular penetrating microelectrodes.

Frontiers in neuroscience

Brunton EK, Winther-Jensen B, Wang C, Yan EB, Hagh Gooie S, Lowery AJ, Rajan R.
PMID: 26283905
Front Neurosci. 2015 May 12;9:265. doi: 10.3389/fnins.2015.00265. eCollection 2015.

Electrodes for cortical stimulation need to deliver current to neural tissue effectively and safely. We have developed electrodes with a novel annular geometry for use in cortical visual prostheses. Here, we explore a critical question on the ideal annulus...

Cite
Brunton EK, Winther-Jensen B, Wang C, et al. In vivo comparison of the charge densities required to evoke motor responses using novel annular penetrating microelectrodes. Front Neurosci. 2015;9:265doi: 10.3389/fnins.2015.00265.
Brunton, E. K., Winther-Jensen, B., Wang, C., Yan, E. B., Hagh Gooie, S., Lowery, A. J., & Rajan, R. (2015). In vivo comparison of the charge densities required to evoke motor responses using novel annular penetrating microelectrodes. Frontiers in neuroscience, 9265. https://doi.org/10.3389/fnins.2015.00265
Brunton, Emma K, et al. "In vivo comparison of the charge densities required to evoke motor responses using novel annular penetrating microelectrodes." Frontiers in neuroscience vol. 9 (2015): 265. doi: https://doi.org/10.3389/fnins.2015.00265
Brunton EK, Winther-Jensen B, Wang C, Yan EB, Hagh Gooie S, Lowery AJ, Rajan R. In vivo comparison of the charge densities required to evoke motor responses using novel annular penetrating microelectrodes. Front Neurosci. 2015 May 12;9:265. doi: 10.3389/fnins.2015.00265. eCollection 2015. PMID: 26283905; PMCID: PMC4518750.
Copy Download .nbib Format: NLM
All-optical OFDM demultiplexing with optical partial Fourier transform and coherent sampling.

Optics letters

Geng Z, Kong D, Corcoran B, Guan P, Da Ros F, Porto da Silva E, Oxenløwe LK, Lowery AJ.
PMID: 30644921
Opt Lett. 2019 Jan 15;44(2):443-446. doi: 10.1364/OL.44.000443.

We propose a novel scheme with a "time-lens"-based partial optical Fourier transform (OFT) and coherent sampling for high-speed complex orthogonal frequency-division multiplexing (OFDM) signal detection. Compared with all-optical OFDM demultiplexing with a matched optical filter, our proposed method replaces...

Cite
Geng Z, Kong D, Corcoran B, et al. All-optical OFDM demultiplexing with optical partial Fourier transform and coherent sampling. Opt Lett. 2019;44(2):443-446doi: 10.1364/OL.44.000443.
Geng, Z., Kong, D., Corcoran, B., Guan, P., Da Ros, F., Porto da Silva, E., Oxenløwe, L. K., & Lowery, A. J. (2019). All-optical OFDM demultiplexing with optical partial Fourier transform and coherent sampling. Optics letters, 44(2), 443-446. https://doi.org/10.1364/OL.44.000443
Geng, Zihan, et al. "All-optical OFDM demultiplexing with optical partial Fourier transform and coherent sampling." Optics letters vol. 44,2 (2019): 443-446. doi: https://doi.org/10.1364/OL.44.000443
Geng Z, Kong D, Corcoran B, Guan P, Da Ros F, Porto da Silva E, Oxenløwe LK, Lowery AJ. All-optical OFDM demultiplexing with optical partial Fourier transform and coherent sampling. Opt Lett. 2019 Jan 15;44(2):443-446. doi: 10.1364/OL.44.000443. PMID: 30644921.
Copy Download .nbib Format: NLM
Testing a Culturally Adapted Colorectal Cancer Screening Decision Aid Among American Indians: Results from a Pre-Post Trial.

Health equity

Frerichs L, Beasley C, Pevia K, Lowery J, Ferrari R, Bell R, Reuland D.
PMID: 32258960
Health Equity. 2020 Apr 01;4(1):91-98. doi: 10.1089/heq.2019.0095. eCollection 2020.

No abstract available.

Cite
Frerichs L, Beasley C, Pevia K, et al. Testing a Culturally Adapted Colorectal Cancer Screening Decision Aid Among American Indians: Results from a Pre-Post Trial. Health Equity. 2020;4(1):91-98doi: 10.1089/heq.2019.0095.
Frerichs, L., Beasley, C., Pevia, K., Lowery, J., Ferrari, R., Bell, R., & Reuland, D. (2020). Testing a Culturally Adapted Colorectal Cancer Screening Decision Aid Among American Indians: Results from a Pre-Post Trial. Health equity, 4(1), 91-98. https://doi.org/10.1089/heq.2019.0095
Frerichs, Leah, et al. "Testing a Culturally Adapted Colorectal Cancer Screening Decision Aid Among American Indians: Results from a Pre-Post Trial." Health equity vol. 4,1 (2020): 91-98. doi: https://doi.org/10.1089/heq.2019.0095
Frerichs L, Beasley C, Pevia K, Lowery J, Ferrari R, Bell R, Reuland D. Testing a Culturally Adapted Colorectal Cancer Screening Decision Aid Among American Indians: Results from a Pre-Post Trial. Health Equity. 2020 Apr 01;4(1):91-98. doi: 10.1089/heq.2019.0095. eCollection 2020. PMID: 32258960; PMCID: PMC7133428.
Copy Download .nbib Format: NLM
Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer.

Cancers

McGuire A, Casey MC, Waldron RM, Heneghan H, Kalinina O, Holian E, McDermott A, Lowery AJ, Newell J, Dwyer RM, Miller N, Keane M, Brown JAL, Kerin MJ.
PMID: 32645898
Cancers (Basel). 2020 Jul 07;12(7). doi: 10.3390/cancers12071820.

Neoadjuvant chemotherapy (NACT) is used in locally advanced breast cancer to reduce tumour burden prior to surgical resection. However, only a subset of NACT treated patients will respond to treatment or achieve a pathologic complete response (pCR). This multicenter,...

Cite
McGuire A, Casey MC, Waldron RM, et al. Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancers (Basel). 2020;12(7)doi: 10.3390/cancers12071820.
McGuire, A., Casey, M. C., Waldron, R. M., Heneghan, H., Kalinina, O., Holian, E., McDermott, A., Lowery, A. J., Newell, J., Dwyer, R. M., Miller, N., Keane, M., Brown, J. A. L., & Kerin, M. J. (2020). Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancers, 12(7), . https://doi.org/10.3390/cancers12071820
McGuire, Andrew, et al. "Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer." Cancers vol. 12,7 (2020). doi: https://doi.org/10.3390/cancers12071820
McGuire A, Casey MC, Waldron RM, Heneghan H, Kalinina O, Holian E, McDermott A, Lowery AJ, Newell J, Dwyer RM, Miller N, Keane M, Brown JAL, Kerin MJ. Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancers (Basel). 2020 Jul 07;12(7). doi: 10.3390/cancers12071820. PMID: 32645898; PMCID: PMC7408914.
Copy Download .nbib Format: NLM
Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events.

Ophthalmology. Retina

Rogers CA, Scott LJ, Reeves BC, Downes S, Lotery AJ, Dick AD, Chakravarthy U.
PMID: 30555977
Ophthalmol Retina. 2018 Feb;2(2):118-127. doi: 10.1016/j.oret.2017.05.015.

PURPOSE: To describe serum vascular endothelial growth factor (sVEGF) in patients with neovascular age-related macular degeneration (nAMD) receiving anti-VEGF agents and associations between sVEGF and systemic serious adverse events (SSAEs).DESIGN: Exploratory analyses of a randomized controlled trial that enrolled...

Cite
Rogers CA, Scott LJ, Reeves BC, et al. Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events. Ophthalmol Retina. 2018;2(2):118-127doi: 10.1016/j.oret.2017.05.015.
Rogers, C. A., Scott, L. J., Reeves, B. C., Downes, S., Lotery, A. J., Dick, A. D., & Chakravarthy, U. (2018). Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events. Ophthalmology. Retina, 2(2), 118-127. https://doi.org/10.1016/j.oret.2017.05.015
Rogers, Chris A, et al. "Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events." Ophthalmology. Retina vol. 2,2 (2018): 118-127. doi: https://doi.org/10.1016/j.oret.2017.05.015
Rogers CA, Scott LJ, Reeves BC, Downes S, Lotery AJ, Dick AD, Chakravarthy U. Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events. Ophthalmol Retina. 2018 Feb;2(2):118-127. doi: 10.1016/j.oret.2017.05.015. PMID: 30555977; PMCID: PMC6278944.
Copy Download .nbib Format: NLM
Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years.

Eye (London, England)

Talks SJ, Stratton I, Peto T, Lotery A, Chakravarthy U, Eleftheriadis H, Izadi S, Dhingra N, Scanlon P.
PMID: 34244672
Eye (Lond). 2022 Jan;36(1):72-77. doi: 10.1038/s41433-021-01625-8. Epub 2021 Jul 09.

INTRODUCTION: Randomised controlled trials provide evidence that a treatment works. Real world evidence is required to assess if proven treatments are effective in practice.METHOD: Retrospective data collection on patients given aflibercept for diabetic macular oedema over 3 years from...

Cite
Talks SJ, Stratton I, Peto T, et al. Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years. Eye (Lond). 2021;36(1):72-77doi: 10.1038/s41433-021-01625-8.
Talks, S. J., Stratton, I., Peto, T., Lotery, A., Chakravarthy, U., Eleftheriadis, H., Izadi, S., Dhingra, N., Scanlon, P. (2022). Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years. Eye (London, England), 36(1), 72-77. https://doi.org/10.1038/s41433-021-01625-8
Talks, S J, et al. "Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years." Eye (London, England) vol. 36,1 (2022): 72-77. doi: https://doi.org/10.1038/s41433-021-01625-8
Talks SJ, Stratton I, Peto T, Lotery A, Chakravarthy U, Eleftheriadis H, Izadi S, Dhingra N, Scanlon P. Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years. Eye (Lond). 2022 Jan;36(1):72-77. doi: 10.1038/s41433-021-01625-8. Epub 2021 Jul 09. PMID: 34244672.
Copy Download .nbib Format: NLM
AAV2/8 Anti-angiogenic Gene Therapy Using Single-Chain Antibodies Inhibits Murine Choroidal Neovascularization.

Molecular therapy. Methods & clinical development

Hughes CP, O'Flynn NMJ, Gatherer M, McClements ME, Scott JA, MacLaren RE, Goverdhan S, Glennie MJ, Lotery AJ.
PMID: 30719487
Mol Ther Methods Clin Dev. 2018 Nov 22;13:86-98. doi: 10.1016/j.omtm.2018.11.005. eCollection 2019 Jun 14.

While anti-angiogenic therapies for wet age-related macular degeneration (AMD) are effective for many patients, they require multiple injections and are expensive and prone to complications. Gene therapy could be an elegant solution for this problem by providing a long-term...

Cite
Hughes CP, O'Flynn NMJ, Gatherer M, et al. AAV2/8 Anti-angiogenic Gene Therapy Using Single-Chain Antibodies Inhibits Murine Choroidal Neovascularization. Mol Ther Methods Clin Dev. 2018;13:86-98doi: 10.1016/j.omtm.2018.11.005.
Hughes, C. P., O'Flynn, N. M. J., Gatherer, M., McClements, M. E., Scott, J. A., MacLaren, R. E., Goverdhan, S., Glennie, M. J., & Lotery, A. J. (2019). AAV2/8 Anti-angiogenic Gene Therapy Using Single-Chain Antibodies Inhibits Murine Choroidal Neovascularization. Molecular therapy. Methods & clinical development, 1386-98. https://doi.org/10.1016/j.omtm.2018.11.005
Hughes, Chris P, et al. "AAV2/8 Anti-angiogenic Gene Therapy Using Single-Chain Antibodies Inhibits Murine Choroidal Neovascularization." Molecular therapy. Methods & clinical development vol. 13 (2019): 86-98. doi: https://doi.org/10.1016/j.omtm.2018.11.005
Hughes CP, O'Flynn NMJ, Gatherer M, McClements ME, Scott JA, MacLaren RE, Goverdhan S, Glennie MJ, Lotery AJ. AAV2/8 Anti-angiogenic Gene Therapy Using Single-Chain Antibodies Inhibits Murine Choroidal Neovascularization. Mol Ther Methods Clin Dev. 2018 Nov 22;13:86-98. doi: 10.1016/j.omtm.2018.11.005. eCollection 2019 Jun 14. PMID: 30719487; PMCID: PMC6350388.
Copy Download .nbib Format: NLM
Prevalence and phenotype associations of complement factor I mutations in geographic atrophy.

Human mutation

Khan AH, Sutton J, Cree AJ, Khandhadia S, De Salvo G, Tobin J, Prakash P, Arora R, Amoaku W, Charbel Issa P, MacLaren RE, Bishop PN, Peto T, Mohamed Q, Steel DH, Sivaprasad S, Bailey C, Menon G, Kavanagh D, Lotery AJ.
PMID: 34153144
Hum Mutat. 2021 Sep;42(9):1139-1152. doi: 10.1002/humu.24242. Epub 2021 Jun 29.

Rare variants in the complement factor I (CFI) gene, associated with low serum factor I (FI) levels, are strong risk factors for developing the advanced stages of age-related macular degeneration (AMD). No studies have been undertaken on the prevalence...

Cite
Khan AH, Sutton J, Cree AJ, et al. Prevalence and phenotype associations of complement factor I mutations in geographic atrophy. Hum Mutat. 2021;42(9):1139-1152doi: 10.1002/humu.24242.
Khan, A. H., Sutton, J., Cree, A. J., Khandhadia, S., De Salvo, G., Tobin, J., Prakash, P., Arora, R., Amoaku, W., Charbel Issa, P., MacLaren, R. E., Bishop, P. N., Peto, T., Mohamed, Q., Steel, D. H., Sivaprasad, S., Bailey, C., Menon, G., Kavanagh, D., & Lotery, A. J. (2021). Prevalence and phenotype associations of complement factor I mutations in geographic atrophy. Human mutation, 42(9), 1139-1152. https://doi.org/10.1002/humu.24242
Khan, Adnan H, et al. "Prevalence and phenotype associations of complement factor I mutations in geographic atrophy." Human mutation vol. 42,9 (2021): 1139-1152. doi: https://doi.org/10.1002/humu.24242
Khan AH, Sutton J, Cree AJ, Khandhadia S, De Salvo G, Tobin J, Prakash P, Arora R, Amoaku W, Charbel Issa P, MacLaren RE, Bishop PN, Peto T, Mohamed Q, Steel DH, Sivaprasad S, Bailey C, Menon G, Kavanagh D, Lotery AJ. Prevalence and phenotype associations of complement factor I mutations in geographic atrophy. Hum Mutat. 2021 Sep;42(9):1139-1152. doi: 10.1002/humu.24242. Epub 2021 Jun 29. PMID: 34153144.
Copy Download .nbib Format: NLM
Ensuring accountability in implementation of supplementary immunisation activities: A case study of the 2017/2018 measles vaccination campaign in Nigeria.

Vaccine

Momoh J, Oteri AJ, Mogekwu F, Onwu N, Dieng B, Bawa S, Braka F, Nsubuga P, Shuaib F.
PMID: 33714654
Vaccine. 2021 Nov 17;39:C12-C20. doi: 10.1016/j.vaccine.2021.02.068. Epub 2021 Mar 11.

INTRODUCTION: Globally, there is a growing concern with accountability and health systems. This has been attributed majorly to discontent with health system performance. Within the Nigerian health system, weak accountability has been consistently singled out as a key challenge...

Cite
Momoh J, Oteri AJ, Mogekwu F, et al. Ensuring accountability in implementation of supplementary immunisation activities: A case study of the 2017/2018 measles vaccination campaign in Nigeria. Vaccine. 2021;39:C12-C20doi: 10.1016/j.vaccine.2021.02.068.
Momoh, J., Oteri, A. J., Mogekwu, F., Onwu, N., Dieng, B., Bawa, S., Braka, F., Nsubuga, P., & Shuaib, F. (2021). Ensuring accountability in implementation of supplementary immunisation activities: A case study of the 2017/2018 measles vaccination campaign in Nigeria. Vaccine, 39C12-C20. https://doi.org/10.1016/j.vaccine.2021.02.068
Momoh, Jenny, et al. "Ensuring accountability in implementation of supplementary immunisation activities: A case study of the 2017/2018 measles vaccination campaign in Nigeria." Vaccine vol. 39 (2021): C12-C20. doi: https://doi.org/10.1016/j.vaccine.2021.02.068
Momoh J, Oteri AJ, Mogekwu F, Onwu N, Dieng B, Bawa S, Braka F, Nsubuga P, Shuaib F. Ensuring accountability in implementation of supplementary immunisation activities: A case study of the 2017/2018 measles vaccination campaign in Nigeria. Vaccine. 2021 Nov 17;39:C12-C20. doi: 10.1016/j.vaccine.2021.02.068. Epub 2021 Mar 11. PMID: 33714654.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 180 entries